Alerts1.28.25
HHS-OIG Issues Favorable Opinion on Drug Manufacturer’s Free Genetic Testing, Counseling for Patients
HHS-OIG recently released Advisory Opinion No. 24-12, a favorable opinion involving a drug manufacturer’s patient support program for individuals who suffer from genetic condition causing chronic kidney stones
The U.S. Department of Health and Human Services’ Office of Inspector General (HHS-OIG) recently released Advisory Opinion No. 24-12, a favorable opinion regarding a drug manufacturer’s program to sponsor genetic testing, related genetic counseling, and disease-state awareness education for certain hereditary conditions that may cause kidney stones. The manufacturer of a drug used to treat chronic kidney stones caused by a rare genetic condition requested the advisory opinion.
Keep Up to Date in a Changing World
Do you want to receive more valuable insights directly in your inbox? Visit our subscription center and let us know what you’re interested in learning more about.
